Akari Therapeutics PLC (AKTX)
1.11
-0.13
(-10.48%)
USD |
NASDAQ |
Nov 22, 12:04
Akari Therapeutics Total Assets (Quarterly): 2.734M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.734M |
| June 30, 2024 | 5.076M |
| March 31, 2024 | 2.772M |
| December 31, 2023 | 4.355M |
| June 30, 2023 | 8.013M |
| June 30, 2022 | 11.37M |
| March 31, 2022 | 19.45M |
| December 31, 2021 | 11.65M |
| September 30, 2021 | 14.72M |
| June 30, 2021 | 4.830M |
| March 31, 2021 | 7.840M |
| December 31, 2020 | 14.60M |
| September 30, 2020 | 13.69M |
| June 30, 2020 | 14.45M |
| March 31, 2020 | 9.969M |
| December 31, 2019 | 6.480M |
| September 30, 2019 | 10.67M |
| June 30, 2019 | 5.151M |
| Date | Value |
|---|---|
| March 31, 2019 | 8.810M |
| December 31, 2018 | 8.030M |
| September 30, 2018 | 12.63M |
| June 30, 2018 | 17.12M |
| March 31, 2018 | 25.50M |
| December 31, 2017 | 29.05M |
| September 30, 2017 | 22.43M |
| June 30, 2017 | 32.05M |
| March 31, 2017 | 36.52M |
| December 31, 2016 | 45.87M |
| September 30, 2016 | 52.07M |
| June 30, 2016 | 57.63M |
| March 31, 2016 | 62.96M |
| December 31, 2015 | 69.89M |
| September 30, 2015 | 79.17M |
| June 30, 2015 | 2.96M |
| March 31, 2015 | 4.317M |
| December 31, 2014 | 3.395M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
2.734M
Minimum
Sep 2024
19.45M
Maximum
Mar 2022
9.501M
Average
8.991M
Median
Total Assets (Quarterly) Benchmarks
| DBV Technologies SA | 93.06M |
| Cellectis SA | 395.88M |
| Adaptimmune Therapeutics PLC | 317.44M |
| Biodexa Pharmaceuticals PLC | 17.67M |
| NuCana PLC | 25.38M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 9.428M |
| Shareholders Equity (Quarterly) | -6.694M |